Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 56 min ago
Peer-reviewedCC BY-NC-ND 4.0Nature Communications

Perk mediates tumor cell fate and therapeutic outcome in response to CDK4/6 inhibition

  • Marganit Farago
  • Bartosz Mucha
  • Varun Samudra
  • Shuyuan Zhang
  • Dariusz Pytel
  • Ata Abbas
  • Polly Phillips-Mason
  • Debora Cavero
  • Masataka Shimonosono
  • Brian S. Henick
  • Hiroshi Nakagawa
  • Kwok-Kin Wong
6 more authors
  • Anil K. Rustgi
  • Constantinos Koumenis
  • Davide Ruggero
  • Yi Fan
  • Serge Y. Fuchs
  • J. Alan Diehl
Open at sourcePDFDOICite

Related

  1. Tarloxotinib targets tumor hypoxia to improve therapeutic efficacy of immune checkpoint inhibition in a MyD88-dependent manner.
    Zhe Fu, Victoria Jackson-Patel, Kathryn Farrand +7
    Journal for immunotherapy of cancerPeer-reviewedCC BY-NCFull textOncologyEurope PMC
  2. Amygdala metabolic activity on FDG PET is associated with survival, response to immune checkpoint inhibition, and tumor immune signaling in non-small cell lung cancer
    B. K. Geist, C. Vraka, C. T. S. Mertel +27
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxiv
  3. Spatially resolved tumor-microenvironment architecture defines therapeutic response in unresectable hepatoblastoma
    Z. Mesrizadeh, M. Ningappa, S. Ranganathan +12
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxivEurope PMC
  4. M2 type tumor-associated macrophage-derived CCL-18 promotes glioma cell proliferation but does not mediates glioma recurrence after radiotherapy
    Jiangpeng Fan, Yufei Mao, Li Liu +7
    ISciencePeer-reviewedCC BY-NC-NDFull textHuman geneticsEurope PMCCrossref
  5. Serglycin-ROS axis mediates synergistic lethality of PI3Kγ inhibition and Azacitidine in TP53-mutated AML
    Guiqin Huang, Xiaoya Cai, Yeming Zhou +3
    BMC CancerPeer-reviewedCC BYFull textOncologyDOAJ

Cite

BibTeXRIS
BibTeX
@article{farago2026perk,
  title = {{Perk mediates tumor cell fate and therapeutic outcome in response to CDK4/6 inhibition}},
  author = {Marganit Farago and Bartosz Mucha and Varun Samudra and Shuyuan Zhang and Dariusz Pytel and Ata Abbas and Polly Phillips-Mason and Debora Cavero and Masataka Shimonosono and Brian S. Henick and Hiroshi Nakagawa and Kwok-Kin Wong and Anil K. Rustgi and Constantinos Koumenis and Davide Ruggero and Yi Fan and Serge Y. Fuchs and J. Alan Diehl},
  journal = {Nature Communications},
  year = {2026},
  month = oct,
  doi = {10.1038/s41467-026-78698-0},
  url = {https://www.nature.com/articles/s41467-026-78698-0},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Perk mediates tumor cell fate and therapeutic outcome in response to CDK4/6 inhibition
AU  - Marganit Farago
AU  - Bartosz Mucha
AU  - Varun Samudra
AU  - Shuyuan Zhang
AU  - Dariusz Pytel
AU  - Ata Abbas
AU  - Polly Phillips-Mason
AU  - Debora Cavero
AU  - Masataka Shimonosono
AU  - Brian S. Henick
AU  - Hiroshi Nakagawa
AU  - Kwok-Kin Wong
AU  - Anil K. Rustgi
AU  - Constantinos Koumenis
AU  - Davide Ruggero
AU  - Yi Fan
AU  - Serge Y. Fuchs
AU  - J. Alan Diehl
PY  - 2026
DA  - 2026/10/17
JO  - Nature Communications
DO  - 10.1038/s41467-026-78698-0
UR  - https://www.nature.com/articles/s41467-026-78698-0
SN  - 2041-1723
ER  -